Natural Flavonoid Inhibits Prostate Cancer Cell Growth
A new laboratory study indicates that the flavonoid Eriocitrin suppresses the activity of androgen-independent prostate cancer cells.
Updated on Oct. 20, 2026 in Cancer
Researchers have identified Eriocitrin as a potent inhibitor of DU145 cell proliferation and migration. The natural flavonoid compound appears to interfere with the signaling pathways that fuel aggressive prostate cancer.
Why it matters
The PI3K/AKT/mTOR signaling pathway is frequently hyperactivated in aggressive prostate cancer, making it a critical target for new therapies. This study provides a foundational step in understanding how natural compounds can disrupt these cellular mechanisms.
Eriocitrin demonstrated the ability to inhibit the PI3K/AKT/mTOR signaling cascade while upregulating E-cadherin expression. Further pharmacokinetic studies are required to establish its potential for clinical application.
The details
The study revealed that Eriocitrin suppresses the spread of androgen-independent prostate cancer by reversing the epithelial-mesenchymal transition process. By inhibiting the PI3K/AKT/mTOR signaling pathway, the compound reduces the invasive capabilities of cancerous cells.
Timeline
October 20, 2026: Researchers published findings detailing the effects of Eriocitrin on prostate cancer cells.
The Big Picture
This discovery shifts the trajectory of prostate cancer research by highlighting a non-synthetic inhibitor of the PI3K/AKT/mTOR signaling pathway. It validates the ongoing effort to identify compounds capable of disrupting cellular pathways that drive aggressive tumor growth.
While this laboratory study provides important insights, it does not currently change existing treatment protocols for patients. Readers should consult with their oncologists regarding established therapeutic options until further in vivo research is completed.
The takeaway
This study highlights the potential of natural compounds to disrupt signaling pathways in aggressive cancers. Future research will focus on determining whether these lab results can be replicated in animal models and eventually clinical settings.
Further reading
For more information on the latest breakthroughs in research, visit the Cancer section.
More information
Read the full results in the peer-reviewed research article.
Source note: This article includes information reported by Nature.
